Well-Rehearsed Valeant Call Unlikely To Stop Deeper Probes
This article was originally published in Scrip
Executive Summary
After days of providing few answers to a lot of unanswered questions, Valeant Pharmaceuticals International Inc. finally explained itself on Oct. 26 in a well-rehearsed morning conference call, which had Evercore ISI analyst Umer Raffat gushing about how well the firm had handled itself after being slow out of the gate.